Jamieson is pleased to announce its role advising founder CEO Jamie Denison-Pender and the management shareholders of Prescient Healthcare Group on the sale of the business to Bridgepoint Development Capital. In addition to significant reinvestment by management, Baird Capital will continue as a minority investor alongside Bridgepoint.
Founded in 2007, Prescient is a global product strategy advisory firm serving the pharmaceutical and biotech industries from its headquarters in London and further offices in the US, India and China. The business provides product strategy services to help its clients make better clinical and commercial decisions, resulting in enhanced outcomes for patients. Prescient works with many of the leading multinational pharmaceutical companies, as well as a growing number of emerging biotech and specialty pharmaceutical organizations.
“The Jamieson team were outstanding. They merged seamlessly with Prescient management and rapidly became a confidant that we couldn’t have done without. Nothing was too much trouble and the advice we received was spot on. I would advise any businesses thinking of embarking on a similar journey to give them a call”
Jamie Denison-Pender, CEO
Tom Burton, Ross Wheeler and Rowan Wright advised the Prescient team.
